Dresden

• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA … Ended recruitment
  2024-515619-23-00 4 2015-06-29 essential thrombocythemia
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges … Halted
  2025-521764-35-01 5 2026-01-27 acute pharyngitis
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas Halted
  2024-519301-36-00 3 2025-07-11 colorectal carcinoma (CRC)
• NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap … Halted
  2024-518841-12-00 9 2025-03-25 HER2 positive resectable esophagogastric adenocarcinoma
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irin … Halted
  2024-512951-18-00 4 2021-08-06 Hepatic Oligometastatic Adenocarcinoma of the Pancreas
• Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended
  2025-522446-51-00 3 2025-10-17 Plaque psoriasis
• Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allerg … Ended
  2024-517014-15-00 10 2025-05-07 Moderate-to-severe allergic rhinitis / rhino-conjunctivitis due to hou
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended
  2024-515615-22-00 4 2025-04-02 Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
• Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with … Ended
  2024-514562-40-00 4 2025-03-13 Hidradenitis suppurativa (HS)
• A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers Ended
  2024-511119-11-00 1 2025-03-07 Advanced or metastatic ovarian cancer, NSCLC, pancreatic cancer, and o
• A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-512380-32-00 1 2025-03-03 esophageal, gastric, or gastroesophageal junction adenocarcinoma
• A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery Ended
  2024-513125-23-00 4 2025-02-28 Patients with moderate to high risk for cardiac surgery associated- ac
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• L19IL2/L19TNF in patients with non-melanoma skin cancer. Ended
  2024-518530-92-00 4 2024-12-09 Patients with high-risk, locally advanced (non-metastatic, node negati
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah

Showing 721–744 of 943 trials